SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

National Association for Continuing Education
Mark Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL

Gregg Sherman, MD
Family Practice
Plantation, FL

: Optimizing Diabetes Care: Evolving Strategies for Safer Integration of Insulin Therapy
Activity/Course #:
: NCME369
: Free
Release/Start Date:
: May 15 2019
Expiration Date:
: May 14 2020
: Primary Care Medicine
Target Audience:
: Primary Care Physicians, Nurse Practitioners, Physician Assistants
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.50 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Due to progressive β-cell dysfunction in type 2 diabetes (T2DM), traditional oral drugs such as metformin and sulfonylureas are often inadequate for achieving/maintaining long-term glycemic control, and ultimately most patients need insulin-providing therapy for managing their disease. However, clinician and patient barriers, including fears of hypoglycemia, lead to underuse of insulin, resulting in unnecessary suboptimal glycemic control. On the other hand, the global epidemic of obesity is contributing T2DM with problematic insulin resistance, necessitating the use of even higher insulin doses, which may lead to glycemic fluctuations that independently contribute to diabetic complications. New preparations of concentrated and long-acting insulins are available and may be appropriate for use in these situations.
This webcast was recorded live at the Conversations in Primary Care 2019 and is being used with the permission of the presenters.
Learning Objectives
After completing this program participants should be able to:
  1. Recognize the risk for, and impact of hypoglycemia in patients with diabetes.
  2. Describe strategies for reducing the of glycemic variability.
  3. Understand effective SMBG vs. newer CGM in managing diabetes and reducing risk of dysglycemia/hypoglycemia.
  4. Differentiate between available insulin preparations and the effects on glycemic variability and hypoglycemic risk.

 How to obtain the CME Certificate

  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 80% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.50 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Dr. Mark Stolar has no relationships to disclose.

Contributing Faculty
Robert S. Busch, MD, FACE has served as a researcher for Novo Nordisk, Sanofi and Amarin. He has also served as a Speaker for Novo Nordisk and Sanofi.

Dr. Javier Morales serves as a speaker for Novo Nordisk, Janssen and Abbott Laboratories. He has also been a member of the Advisory Board for Eli Lilly and has served as a consultant for Novo Nordisk and Eli Lilly.

Activity Planning Committe
Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Killbridge, Medical Writer, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Daniela Hiedra, BA, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit